Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization

  • End date
    Mar 22, 2023
  • participants needed
  • sponsor
    University of Chicago
Updated on 22 January 2021


Contrast agent is typically used during routine cardiac intervention in order to enhance the imaging necessary to perform the procedure. Using this contrast agent could lead to kidney injury, called contrast induced nephropathy (CIN). Currently, the methods used to reduce the risk of CIN include reducing the amount of contrast agent used and using a hydration strategy during procedure. A computer-based risk tool has been developed which reports a risk score for the likelihood a person undergoing cardiac intervention gets CIN and a proposed corresponding hydration strategy to reduce the risk of CIN. The purpose of this study is to determine whether the rate of CIN decreases when the treating physician has access to this risk tool during the procedure.


This is a case-control series comparing a strategy using a computer-based contrast induced nephropathy (CBCIN) risk tool in patients undergoing PCI versus usual care. Only inpatients will be included in this study. These inpatients will be compared to historical controls obtained using the medical record of age- and gender-matched inpatients who underwent cardiac catheterization with at least two consecutive daily post-procedure creatinine values. The percentage PCI will be matched in the retrospective series.

In the prospective group, the operator will be exposed to the CBCIN risk tool before and during care delivery with estimated CIN risk. The CBCIN risk tool estimates CIN risk based on the status of known risk factors (and suggests an associated standard hydration strategy based on left-ventricular end-diastolic pressure), which are automatically prepared from the patient's Electronic Medical Record and presented to the operator for review. This functionality has been evaluated in previous research and was found to be stable and reliable. Based on the data presented by and reviewed in the CBCIN risk tool, the operator may use the information and adjust therapy as clinically indicated (i.e. the risk tool is not the basis for clinical decisions). Following the PCI, serum creatinine will be measured as per treating physician, but those who undergo at least two consecutive daily serum creatinine measurements starting the day after the procedure will be included in the study. These patients will be called 6 months and 12 months post-procedure to determine mortality and re-hospitalization status.

Condition Contrast Induced Nephropathy
Treatment Exposure to CBCIN risk score
Clinical Study IdentifierNCT03305874
SponsorUniversity of Chicago
Last Modified on22 January 2021


Yes No Not Sure

Inclusion Criteria

Inpatients age 21 years seen at the University of Chicago Medical Center with
a clinical indication for cardiac catheterization with high likelihood of PCI
or those undergoing planned PCI will be screened for enrollment into our
study. Following PCI, these patients must have at least two consecutive daily
creatinine measurements starting the day after the PCI, but clinically-
indicated according to the inpatient treating physician

Exclusion Criteria

Patients being discharged the day after the PCI
Patients who are screened but do not receive PCI
Patients who do not have at least two consecutive daily creatinine measurements starting the day after the PCI
Patients undergoing emergency primary percutaneous coronary intervention for ST-segment elevation myocardial infarction
Patients in cardiogenic shock
Patients with end-stage renal disease or who are on renal replacement therapy
Patients requiring planned mechanical circulatory support for the PCI
Pregnant women (standard PCI screening)
Vulnerable populations such as children, college students, prisoners, non-English speakers, and those with diminished decision-making capacity
Inability or refusal to consent for the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note